Clinical Trial Update: Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff [Phase 3]

View source ↗

Summary

Phase 3 trial update for rhIFNα nasal drops aimed at preventing 2019-nCOV infection in medical staff; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• 2019 Novel Coronavirus Infection

Drugs mentioned

• rhIFNα nasal drops (recombinant human interferon alpha nasal drops)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: 2019 Novel Coronavirus Infection | Phase 3 | Status: UNKNOWN